Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Omacetaxine mepesuccinate homoharringtonine: Preliminary Phase II/III data

CXS reported preliminary data from the first 21 CML patients in an ongoing Phase II/III

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE